SEC Form 4 · accession 0000899243-16-026928

China Biologic Products, Inc. · CBPO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1On August 11, 2016, WP X Biologics LLC, a Delaware limited liability company ("WP X B") made an in-kind distribution, without additional consideration to its members, of that number of shares of common stock ("Common Stock") of the Issuer set forth in column 4.
• F2The 6,674 shares of Common Stock of the Issuer are held by WP X B. Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X") is a holder of 96.9% of the equity interest in WP X B, and Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X"), is a holder of 3.1% of the equity interest in WP X B. WPP X together with WP X are collectively the "Funds". Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") is the general partner of each of the Funds. Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), is the general partner of WP X LP. WPP GP LLC, a Delaware limited liability company ("WPP GP") is the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"),
• F3(continued from Footnote 2) is the general partner of WP Partners. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP LLC. Warburg Pincus LLC, a New York limited liability company ("WP LLC"), manages each of the Funds. Charles R. Kaye and Joseph P. Landy are each Managing General Partners of WP and Managing Members and Co-Chief Executive Officers of WP LLC, and may be deemed to control WP X B, the Funds, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP, WP LLC, Mr. Kaye and Mr. Landy may be deemed to be the beneficial owners of any securities that may be beneficially owned by WP X B and the Funds.
• F4(continued from Footnote 2) Each of WP X LP, WP X GP, WP Partners, WP GP LLC, WP, WP LLC, Mr. Kaye and Mr. Landy disclaim beneficial ownership of all shares of Common Stock that may be deemed to be beneficially owned by WP X B and the Funds, except to the extent of any indirect pecuniary interest therein.
• F5Mr. Fang is a Managing Director and Member of WP LLC. As such, Mr. Fang may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Exchange Act) in an indeterminate portion of the securities reported as beneficially owned by the Funds and WP X B. Mr. Fang disclaims beneficial ownership of such securities, except to the extent of any direct pecuniary interest therein.
• F6On August 11, 2016, Mr. Fang directly received the shares noted in column 5 in connection with the distribution set forth in footnote 1 above.